Physician profile
Kevin B Smith
NPI 1700855780
$1,348.28
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,130 · 2020: $218.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $253.19 | 2019-2020 | |
| Glaxosmithkline, LLC. | $174.54 | 2019 | |
| Janssen Pharmaceuticals, INC | $164.82 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $151.53 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $127.16 | 2019-2020 | |
| Abbvie INC. | $93.64 | 2019-2020 | |
| Shire North American Group INC | $83.80 | 2019 | |
| Allergan, INC. | $41.49 | 2019 | |
| Pfizer INC. | $39.93 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $36.16 | 2019 | |
| Novo Nordisk INC | $29.79 | 2019 | |
| Sanofi Pasteur INC. | $29.61 | 2019 | |
| Novartis Pharmaceuticals Corporation | $26.99 | 2019 | |
| Edwards Lifesciences Corporation | $21.41 | 2020 | |
| Aytu Biopharma, INC. | $20.64 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Antares Pharma, INC. | $15.01 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $14.33 | 2019 | |
| Arbor Pharmaceuticals, INC. | $12.37 | 2020 | |
| Amarin Pharma, INC. | $11.87 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.